Cephalosporin Market Analysis - Global Industry Size, Share, Trends and Forecast, 2018 - 2026

Category : Healthcare and Pharmaceuticals | Delivery Format : PDF | Status: Forthcoming | Report ID : ARC530


Cephalosporins are one of the largest and most diverse family of antibiotics of the bactericidal β-lactam group. Based on their antimicrobial activity, they are grouped into various type of generations. Cephalosporin inhibits enzymes in the cell wall of susceptible bacteria, hence disrupting cell synthesis. Increasing research and development activities, and increasing demand for antibacterial drugs is propelling the growth of cephalosporin market.

Market Dynamics

The market for cephalosporin would continue to rise immensely with the aging population and increasing incidences of infectious diseases worldwide. Cephalosporin have a broad range of therapeutic application and are effective in the treatment of streptococcal, pneumococcal, staphylococcal, Klebsiella, Escherichia coli and Proteus infections. One of the significant roles of cephalosporin has been as chemoprophylactic agents at the time of surgical procedures. In addition, cephalosporin has the ability to retain excellent pharmacokinetic properties, hence making cephalosporin drugs as the first choice for treatment of various infections. However, factors such as certain side-effects associated with cephalosporin and development of drug-resistant bacterial strains might restrain the growth of cephalosporin market.

Market Classification and Overview

The cephalosporin market is segmented on the basis of generation, route of administration, type, application and geography. Based on route of administration, the market is segmented into oral and injection. The injection route of administration is anticipated to grow swiftly during the forecast period owing to its ease-of-use, and better patient compliance.

Based on application, the global market has been bifurcated into sexually transmitted infection, respiratory tract infection, skin infection, ear infection, and urinary tract infection. Sexually transmitted infection dominated the application segment in 2016. Factors such as increasing number of people suffering from sexually transmitted diseases, and excellent efficacy of cephalosporin as antibiotics are driving the market growth. According to the WHO, more than 1 million sexually transmitted infections are acquired each day worldwide.

Regional Overview

Regionally, the market for cephalosporin is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle-East and Africa (MEA). North America is dominating the global market owing to the presence of highly advanced healthcare facilities, and presence of large number of patient population affected with sexually transmitted diseases. However, Asia-Pacific is expected to grow at the fastest CAGR due to increased population base, growing disposable income in countries like China and India, and beneficial government initiatives.

Report Coverage


Cephalosporin Market

Analysis Period

2015 – 2026

Historic Data

2015 – 2016

Base Year


Forecast Data

2018 – 2026

Market Stratification

Generation, Route of Administration, Type, Application, Geography

Regional Scope

North America, Europe, Asia-Pacific, Latin America, Middle East and Africa (MEA)

Report Coverage

Market Trends, Drivers, Restraints, Porter's Five Forces Analysis, Competitive Analysis,

Player Profiling, Value Chain Analysis

Market Participants

F. Hoffmann-La Roche Ltd., Lupin Limited, Bristol-Myers Squibb Company, Pfizer Inc., Eli Lilly and Company, Allergan Plc, GlaxoSmithKline Plc, Merck & Co., Inc., Sanofi, and Teva Pharmaceutical Industries Ltd. are the key players in the cephalosporin market. These players have undertaken mergers and acquisitions as one of their key strategies in order to maximize their share in the global market.

Market Segmentation

Market By Generation

·         First Generation

·         Second Generation

·         Third Generation

·         Fourth Generation

·         Fifth Generation

Market By Route of Administration

·         Oral

·         Injection

Market By Type

·         Branded

·         Generic

Market By Application

·         Sexually Transmitted Infection

·         Respiratory Tract Infection

·         Skin Infection

·         Ear Infection

·         Urinary Tract Infection

Market By Geography

·         North America

o   US

o   Canada

o   Mexico

·         Europe

o   UK

o   Germany

o   France

o   Rest of Europe

·         Asia-Pacific

o   China

o   Japan

o   India

o   Australia

o   Rest of Asia-Pacific

·         Latin America

o   Brazil

o   Rest of Latin America

·         Middle East and Africa (MEA)

o   South Africa

o   Saudi Arabia

o   Rest of MEA

Cart Summary